

# Clinical trials of EGFR inhibitors for lung cancer (metastatic) in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 ALK inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>ceritinib vs chemotherapy</b>			
<b>ASCEND-4 , 2017</b> [NCT01828099] n=NA follow-up:	oral ceritinib 750 mg/day versus platinum-based chemotherapy ([cisplatin 75 mg/m <sup>2</sup> or carboplatin AUC 5-6 plus pemetrexed 500 mg/m <sup>2</sup> ] every 3 weeks for four cycles followed by maintenance pemetrexed	untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC	
<b>crizotinib vs chemotherapy</b>			
<b>Shaw , 2013</b> [NCT00932893] n=NA follow-up:	crizotinib (250 mg) twice daily versus intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks	patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen	Parallel groups open-label
<b>PROFILE 1014 , 2014</b> [NCT01154140] n=172/171 follow-up: 16.7 months	oral crizotinib, at a dose of 250 mg twice daily versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin	Patients With ALK Positive Non Squamous Cancer Of The Lung	
<b>A8081029 ongoing</b> [NCT01639001] n=NA follow-up:	-	Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients	china
<b>alectinib vs crizotinib</b>			
<b>ALEX , 2017</b> [NCT02075840] n=152/151 follow-up:	alectinib 600 mg orally (four 150 mg capsules) BID versus Crizotinib	patients with stage IIIB or IV, ALK-positive NSCLC who had not received prior systemic therapy	Parallel groups open label USA
<b>YO29449 ongoing</b> [NCT02838420] n=NA follow-up:	alectinib capsules orally at a dose of 600 mg BID versus crizotinib capsules orally at a dose of 250 mg BID	asian participants with treatment-naive ALK-positive advanced NSCLC	China
<b>brigatinib vs crizotinib</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>ALTA-1L</b> <i>ongoing</i> [NCT02737501] n=NA follow-up:	Brigatinib 90 mg QD for 7 days, then 180 mg QD, continuously versus Crizotinib 250 mg orally BID	ALK-positive Advanced Lung Cancer Patients	USA
<b>ensartinib vs crizotinib</b>			
<b>X396-CLL-301</b> <i>ongoing</i> [NCT02767804] n=NA follow-up:	ensartinib 225mg QD versus oral crizotinib at 250mg BID	patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor	USA
<b>lorlatinib vs crizotinib</b>			
<b>B7461006</b> <i>ongoing</i> [NCT03052608] n=NA follow-up:	Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously versus Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously	advanced ALK-positive NSCLC patients who are treatment nave	
<b>ceritinib vs pemetrexed or docetaxel</b>			
<b>CLDK378A2303</b> <i>ongoing</i> [NCT01828112] n=NA follow-up:	Oral LDK378 750 mg once daily versus pemetrexed or docetaxel	patients previously treated with chemotherapy (platinum doublet) and crizotinib	USA
<b>crizotinib vs placebo</b>			
<b>E4512</b> <i>ongoing</i> [NCT02201992] n=NA follow-up:	-	Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations	
<b>alectinib vs premetrexed or docetaxel</b>			
<b>MO29750</b> <i>ongoing</i> [NCT02604342] n=NA follow-up:	oral alectinib at a dosage of 600 mg BID versus either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter)	participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib	Belgium

## References

### ASCEND-4, 2017:

Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet* 2017 Jan 23; [28126333] [10.1016/S0140-6736\(17\)30123-X](https://doi.org/10.1016/S0140-6736(17)30123-X)

### Shaw, 2013:

Shaw AT, Kim DW, Nakagawa K, Seto T, Crin L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jnne PA Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94 [23724913]

### PROFILE 1014, 2014:

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med* 2014;371:2167-77 [25470694]

### A8081029, 0:

**ALEX, 2017:**

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Prol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T  
 Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017 Jun 6; [[28586279](#)] [10.1056/NEJMoa1704795](#)

**YO29449, 0:****ALTA-1L, 0:****X396-CLI-301, 0:****B7461006, 0:****CLDK378A2303, 0:****E4512, 0:****MO29750, 0:**

## 2 monoclonal antibody

Trial	Treatments	Patients	Trials design and methods
<b>vs</b>			
<b>SQUIRE</b> [NCT00981058] n=NA	-	-	
<b>INSPIRE</b> [NCT00982111] n=NA	-	-	
<b>cetuximab vs CT</b>			
<b>65279;Lynch , 2010</b> n=NA follow-up:	cetuximab (400 mg/m <sup>2</sup> ) on day 1, 250 mg/m <sup>2</sup> weekly) was administered until progression or unacceptable toxicity plus taxane/carboplatin versus paclitaxel (225 mg/m <sup>2</sup> ) or docetaxel (75 mg/m <sup>2</sup> ), at the investigator's discretion, and carboplatin (area under the curve = 6) on day 1 every 3 weeks for <or = six cycles	chemotherapy-naïve patients with stage IIIB (pleural effusion) or IV NSCLC, without restrictions by histology or epidermal growth factor receptor expression	open-label
<b>cetuximab vs CT alone</b>			
<b>Butts , 2007</b> n=65/66 follow-up:	cetuximab (400 mg/m <sup>2</sup> i.v versus cisplatin (75 mg/m <sup>2</sup> i.v., every 3 weeks) or carboplatin (area under the concentration-versus-time curve of 5 intravenously [i.v.], every 3 weeks), and gemcitabine (1,250 or 1,000 mg/m <sup>2</sup> i.v., days 1 and 8)	chemotherapy-naïve patients with recurrent/metastatic NSCLC (stage IV or stage IIIB with malignant pleural effusion)	
<b>cetuximab + CT vs CT alone</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>FLEX (Pirker) , 2009</b> [NCT00148798] n=557/568 follow-up:	Cetuximab-at a starting dose of 400 mg/m(2) intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m(2) over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity + CT versus cisplatin 80 mg/m(2) intravenous infusion on day 1, and vinorelbine 25 mg/m(2) intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles	chemotherapy-naive patients with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer	open-label
<b>Rosell , 2008</b> n=43/43 follow-up:	cetuximab treatment (initial dose 400 mg/m(2), followed by 250 mg/m(2) weekly thereafter) + same CT versus for a maximum of eight cycles, patients received three-weekly cycles of cisplatin (80 mg/m(2), day 1) and vinorelbine (25 mg/m(2) on days 1 and 8) alone	first-line therapy in EGFR-expressing advanced non-small-cell lung cancer	

## References

### SQUIRE, :

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Blint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. *Lancet Oncol* 2015;16:763-74 [26045340]

### INSPIRE, :

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramla Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. *Lancet Oncol* 2015;16:328-37 [25701171]

### 65279;Lynch, 2010:

Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* 2010;28:911-7 [20100966]  
10.1200/JCO.2009.21.9618

### Butts, 2007:

Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. *J Clin Oncol* 2007;25:5777-84 [18089875] 10.1200/JCO.2007.13.0856

### FLEX (Pirker), 2009:

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009;373:1525-31 [19410716] 10.1016/S0140-6736(09)60569-9

### Rosell, 2008:

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. *Ann Oncol* 2008;19:362-9 [[17947225](#)] [10.1093/annonc/mdm474](#)

### 3 TKI

Trial	Treatments	Patients	Trials design and methods
<b>gefitinib vs</b>			
West Japan n=NA	-	-	
Northeast Japan n=NA	-	-	
CTONG0806 (Yang) , 2013 n=NA	-	-	
<b>gefitinib vs carboplatin-paclitaxel</b>			
NEJ002 , 2013 n=NA	-	chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations	
Maemondo , 2010 [UMIN-CTR C000000376] n=NA	-	patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy	
IPASS (Mok) , 2009 [NCT00322452] n=NA follow-up:	-	previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers	
<b>gefitinib vs carboplatin/paclitaxel</b>			
IPASS n=NA follow-up:	-	previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma	
<b>afatinib vs Chemotherapy</b>			
1200.34 <i>ongoing</i> [NCT01121393] n=NA follow-up:	tablet of BIBW 2992 daily until progression or unacceptable toxicity versus Gemcitabine and Cisplatin, maximum is 6 courses	patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation	open label china
1200.42 <i>ongoing</i> [NCT01085136] n=NA follow-up:	BIBW 2992 and Paclitaxel versus Investigator's choice of chemotherapy	patients with NSCLC Stage IIIB or IV progressing after BIBW 2992 monotherapy	open label argentina
<b>gefitinib vs cisplatin plus docetaxel</b>			
WJTOG3405 (Mitsudomi) , 2010 n=NA	-	patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor	
<b>afatinib vs cisplatin-based chemotherapy</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
LUX-LUNG 3 , 2015 n=NA	-	EGFR mutation-positive lung adenocarcinoma	
LUX-LUNG 6 , 2015 n=NA	-	EGFR mutation-positive lung adenocarcinoma	
<b>afatinib vs Cisplatin/Pemetrexed</b>			
1200.32 <i>ongoing</i> [NCT00949650] n=NA follow-up:	BIBW 2992 tablet once daily until progression versus (Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles	patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation	open label
<b>gefitinib vs continued platinum-doublet chemotherapy</b>			
WJTOG0203 (Takeda) , 2010 n=NA	-	Japanese patients with advanced non-small-cell lung cancer	
<b>gefitinib vs docetaxel</b>			
ISTANA (Lee) , 2010 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
V-15-32 (Maruyama) , 2008 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
INTEREST (Kim) , 2008 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
SIGN (Cufer) , 2006 n=NA	-	previously treated advanced nonsmall-cell lung cancer	
IFCT-0301 study (Morre) , 2010 n=NA	-	patients with advanced non-small-cell lung cancer and a performance status of 2 or 3	
<b>afatinib vs Erlotinib</b>			
LUX-LUNG 8 <i>ongoing</i> [NCT01523587] n=NA follow-up:	afatinib tablets once daily versus erlotinib tablets once daily	patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy	open label
<b>gefitinib vs gefitinib</b>			
Kris , 2003 n=NA follow-up:	-	Patients either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens	double blind
<b>gefitinib vs gemcitabine and cisplatin</b>			
First Signal n=159/150 follow-up:	gefitinib (250 mg daily) versus GP chemotherapy (gemcitabine 1,250 mg/m <sup>2</sup> ) on days 1 and 8; cisplatin 80 mg/m <sup>2</sup> ) on day 1 every 3 weeks, for up to nine courses	first-line therapy of never-smokers with adenocarcinoma of the lung	
<b>gefitinib paclitaxel and carboplatin vs paclitaxel and carboplatin</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>INTACT 2 , 2004</b> n=NA follow-up:	gefitinib plus paclitaxel and carboplatin versus paclitaxel 225 mg/m <sup>2</sup> and carboplatin area under concentration/time curve of 6 mg/min/mL (day 1 every 3 weeks)	chemotherapy-naive patients with advanced NSCLC	double-blind
<b>afatinib vs placebo</b>			
<b>LUX-LUNG 1</b> <i>ongoing</i> [NCT00656136] n=NA follow-up:	BIBW 2992 tablets once daily versus Placebo	patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed	double-blind
<b>gefitinib vs placebo</b>			
<b>NCIC CTG BR19 (Goss) , 2013</b> n=NA follow-up:	gefitinib 250 mg per day versus placebo	completely resected non-small-cell lung cancer	double-blind
<b>INFORM; C-TONG 0804 , 2012</b> [NCT00770588] n=NA	-	maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer	
<b>EORTC 08021/ILCP 01/03 , 2011</b> [NCT00091156] n=NA	-	patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy	
<b>Goss , 2009</b> n=NA	-	chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status	
<b>SWOG S0023 (Kelly) , 2008</b> n=NA	-	inoperable stage III non-small-cell lung cancer	
<b>ISEL , 2006</b> n=NA	-	patients of Asian origin with refractory advanced non-small cell lung cancer	
<b>Tsuboi , 2005</b> n=NA	-	patients with completely resected non-small cell lung cancer	
<b>osimertinib vs placebo</b>			
<b>FLAURA</b> [NCT02296125] n=279/277 follow-up:	osimertinib (AZD9291) (80 mg or 40 mg orally, once daily) versus first-line standard-of-care treatment erlotinib or gefitinib	previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutationpositive nonsmall cell lung cancer	Parallel groups double-blind
<b>gefitinib + gemcitabine/cisplatin vs placebo + gemcitabine / cisplatin</b>			
<b>INTACT 1.</b> n=NA follow-up:	gefitinib 500 mg/d, gefitinib 250 mg/d, versus placebo	chemotherapy-naive patients with unresectable stage III or IV NSCLC	double blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>erlotinib vs Platinum-based CT</b>			
<b>OPTIMAL</b> [ NCT00874419] n=83/82 follow-up:	oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects versus up to four cycles of gemcitabine plus carboplatin	Patients older than 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation)	open-label
<b>EUTRAC</b> [ NCT00446225] n=NA follow-up:	oral erlotinib 150 mg per day versus 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8).	adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending 6 months before study entry was allowed)	open-label
<b>TITAN</b> [ NCT00556322] n=NA follow-up:	erlotinib 150 mg/day versus chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion) until unacceptable toxicity, disease progression, or death	second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis	open-label
<b>erlotinib + Platinum-based CT vs Platinum-based CT</b>			
<b>TRIBUTE (65279;Herbst)</b> n=526/533 follow-up:	erlotinib 150 mg/d combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib versus placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib	patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC	
<b>Gatzemeier</b> n=579/580 follow-up:	Erl 150 mg/day plus (Gem 1,250 mg/m2 D1,8 and Cis 80 mg/m2 D1)*6 cycles versus Gem 1,250 mg/m2 D1,8 and Cis 80 mg/m2 D1)*6 cycles	first-line treatment for advanced non-small-cell lung cancer	
<b>Mok</b> n=57/57 follow-up:	Erl 150 mg/day plus (Gem 1,250 mg/m2 D1,8 and either Cis75 mg/m2 D1 or Car AUC = 5, D1) versus Gem 1,250 mg/m2 D1,8 and either	first-line treatment for advanced non-small-cell lung cancer	
<b>SATURN (Cappuzzo)</b> [ NCT00556712] n=438/451 follow-up:	Erl 150 mg/day plus select one of seven standard chemotherapy regimens versus Cis75 mg/m2 D1 or Car AUC = 5, D1	maintenance treatment in advanced non-small-cell lung cancer	
<b>Boutsikou</b> n=52/61 follow-up:	Erl 150 mg/day plus (Doc 100 mg/ m 2 and Car AUC = 5.5 q28d*4) versus Doc 100 mg/m2 and Car AUC = 5.5 q28d*4	first-line treatment of patients with NSCLC	

continued...



Trial	Treatments	Patients	Trials design and methods
Lee [ NCT00550173] n=78/80 follow-up:	Erl 150 mg/day plus Pem 500 mg/ m 2 D1 q21d versus Pem 500 mg/m2 D1 q21d	second-line treatment for never-smokers with non-squamous non-small cell lung cancer	
Stinchcombe n=51/44 follow-up:	Erl 150 mg/day plus Gem 1,200 mg/m2 D1,8 q21d versus Gem 1,200 mg/m2 D1,8 q21d	elderly patients (age 70 years) with stage IIIB or IV non-small cell lung cancer	
FASTACT-2 (Wu) [ NCT00883779] n=226/255 follow-up:	Erl 150 mg/day plus Gem 1,250 mg/m2 D1,8, six cycles and Car AUC = 5 or Cis 75 mg/ m 2,D1 versus Gem 1,250 mg/m2, d1,8, six cycles and Car AUC = 5 or Cis 75 mg/ m 2,D1	patients with untreated stage IIIB/IV non-small-cell lung cancer	
<b>osimertinib vs platinum-based therapy plus pemetrexed</b>			
AURA 3 , 2017 [NCT02151981] n=NA follow-up:	oral osimertinib (at a dose of 80 mg once daily) versus intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles	patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy.	
<b>gefitinib vs vinorelbine</b>			
INVITE (Crin) , 2008 [NCT00256711] n=NA	-	chemotherapy-naive elderly patients with advanced non-small-cell lung cancer	

## References

West Japan, :

Northeast Japan, :

**CTONG0806 (Yang), 2013:**

**NEJ002, 2013:**

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). *Ann Oncol* 2013;24:54-9. [22967997] [10.1093/annonc/mds214](#)

**Maemondo, 2010:**

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8. [20573926] [10.1056/NEJMoa0909530](#)

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, , Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8. [20573926] [10.1056/NEJMoa0909530](#)

**IPASS (Mok), 2009:**

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57. [19692680] [10.1056/NEJMoa0810699](https://doi.org/10.1056/NEJMoa0810699)

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Ru Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. *Lung Cancer* 2017;104:119-125 [28212993]

#### **IPASS, :**

Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS, Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). *Lung Cancer* 2014;83:174-81. [24361280] [10.1016/j.lungcan.2013.11.021](https://doi.org/10.1016/j.lungcan.2013.11.021)

Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M, Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. *Asia Pac J Clin Oncol* 2012;8:232-43. [22897752] [10.1111/j.1743-7563.2012.01518.x](https://doi.org/10.1111/j.1743-7563.2012.01518.x)

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenzov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol* 2011;29:2866-74. [21670455] [10.1200/JCO.2010.33.4235](https://doi.org/10.1200/JCO.2010.33.4235)

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57 [19692680]

**1200.34, 0:**

**1200.42, 0:**

#### **WJTOG3405 (Mitsudomi), 2010:**

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, , Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8. [20022809] [10.1016/S1470-2045\(09\)70364-X](https://doi.org/10.1016/S1470-2045(09)70364-X)

#### **LUX-LUNG 3, 2015:**

Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bannouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Se Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 2015;16:141-51. [25589191] [10.1016/S1470-2045\(14\)71173-8](https://doi.org/10.1016/S1470-2045(14)71173-8)

Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV, Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3342-50. [23816967] [10.1200/JCO.2012.46.1764](https://doi.org/10.1200/JCO.2012.46.1764)

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bannouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3327-34. [23816960] [10.1200/JCO.2012.44.2806](https://doi.org/10.1200/JCO.2012.44.2806)

#### **LUX-LUNG 6, 2015:**

Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bannouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Se Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 2015;16:141-51. [25589191] [10.1016/S1470-2045\(14\)71173-8](https://doi.org/10.1016/S1470-2045(14)71173-8)

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15:213-22. [24439929] [10.1016/S1470-2045\(13\)70604-1](https://doi.org/10.1016/S1470-2045(13)70604-1)

**1200.32, 0:**

**WJTOG0203 (Takeda), 2010:**

Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M, Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). *J Clin Oncol* 2010;28:753-60. [20038730] [10.1200/JCO.2009.23.3445](https://doi.org/10.1200/JCO.2009.23.3445)

**ISTANA (Lee), 2010:**

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. *Clin Cancer Res* 2010;16:1307-14 [20145166] [10.1158/1078-0432.CCR-09-1903](https://doi.org/10.1158/1078-0432.CCR-09-1903)

**V-15-32 (Maruyama), 2008:**

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. *J Clin Oncol* 2008;26:4244-52 [18779611] [10.1200/JCO.2007.15.0185](https://doi.org/10.1200/JCO.2007.15.0185)

Yamamoto N, Nishiwaki Y, Negoro S, Jiang H, Itoh Y, Saijo N, Fukuoka M, Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. *J Thorac Oncol* 2010;5:1042-7. [20453692] [10.1097/JTO.0b013e3181da36db](https://doi.org/10.1097/JTO.0b013e3181da36db)

Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M, Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. *Ann Oncol* 2009;20:1483-8. [19282468] [10.1093/annonc/mdp031](https://doi.org/10.1093/annonc/mdp031)

**INTEREST (Kim), 2008:**

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet* 2008;372:1809-18 [19027483] [10.1016/S0140-6736\(08\)61758-4](https://doi.org/10.1016/S0140-6736(08)61758-4)

**SIGN (Cufer), 2006:**

Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. *Anticancer Drugs* 2006;17:401-9 [16549997] [10.1097/01.cad.0000203381.99490.ab](https://doi.org/10.1097/01.cad.0000203381.99490.ab)

**IFCT-0301 study (Morre), 2010:**

Morre JF, Brchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlsi F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D, Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). *Lung Cancer* 2010;70:301-7. [20400201] [10.1016/j.lungcan.2010.03.003](https://doi.org/10.1016/j.lungcan.2010.03.003)

**LUX-LUNG 8, 0:**

**Kris, 2003:**

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA* 2003;290:2149-58 [14570950]

**First Signal, :**

Lee Y, Han JY, Kim HT, Yun T, Lee GK, Kim HY, Lee JS, Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. *J Neurooncol* 2013;115:95-101. [23832498] [10.1007/s11060-013-1199-y](https://doi.org/10.1007/s11060-013-1199-y)

Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol* 2012;30:1122-8. [22370314] [10.1200/JCO.2011.36.8456](https://doi.org/10.1200/JCO.2011.36.8456)

**INTACT 2, 2004:**

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. *J Clin Oncol* 2004;22:785-94 [[14990633](#)]

#### **LUX-LUNG 1, 0:**

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol* 2012;13:528-38 [[22452896](#)]

Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC, Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). *J Thorac Oncol* 2013;8:229-37. [[23328549](#)] [10.1097/JTO.0b013e3182773fce](#)

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol* 2012;13:528-38. [[22452896](#)] [10.1016/S1470-2045\(12\)70087-6](#)

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol* 2012;13:528-38. [[22452896](#)] [10.1016/S1470-2045\(12\)70087-6](#)

#### **NCIC CTG BR19 (Goss), 2013:**

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA, Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. *J Clin Oncol* 2013;31:3320-6. [[23980091](#)] [10.1200/JCO.2013.51.1816](#)

#### **INFORM; C-TONG 0804, 2012:**

Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M, , Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. *Lancet Oncol* 2012;13:466-75. [[22512843](#)] [10.1016/S1470-2045\(12\)70117-1](#)

#### **EORTC 08021/ILCP 01/03, 2011:**

Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, , A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). *Eur J Cancer* 2011;47:2331-40. [[21802939](#)] [10.1016/j.ejca.2011.06.045](#)

#### **Goss, 2009:**

Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, Hirsch FR, Varella-Garcia M, Duffield E, Ataman OU, Zarenda M, Armour AA, Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. *J Clin Oncol* 2009;27:2253-60. [[19289623](#)] [10.1200/JCO.2008.18.4408](#)

#### **SWOG S0023 (Kelly), 2008:**

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. *J Clin Oncol* 2008;26:2450-6. [[18378568](#)] [10.1200/JCO.2007.14.4824](#)

#### **ISEL, 2006:**

Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N, Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. *J Thorac Oncol* 2006;1:847-55. [[17409969](#)]

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* ;366:1527-37. [[16257339](#)] [10.1016/S0140-6736\(05\)67625-8](#)

#### **Tsuboi, 2005:**

Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, Ichinose Y, Fukuoka M, Jiang H, Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. *Anticancer Drugs* 2005;16:1123-8. [[16222155](#)]

**FLAURA, :**

**INTACT 1., :**

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. *J Clin Oncol* 2004;22:777-84. [[14990632](#)] [10.1200/JCO.2004.08.001](#)

**OPTIMAL , :**

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735-42 [[21783417](#)] [10.1016/S1470-2045\(11\)70184-X](#)

**EUTRAC, :**

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Regu Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239-46 [[22285168](#)] [10.1016/S1470-2045\(11\)70393-X](#)

**TITAN, :**

Ciuleanu T, Stelmakh L, Cicenias S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. *Lancet Oncol* 2012;13:300-8 [[22277837](#)] [10.1016/S1470-2045\(11\)70385-0](#)

Ciuleanu T, Stelmakh L, Cicenias S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. *Lancet Oncol* 2012;13:300-8 [[22277837](#)] [10.1016/S1470-2045\(11\)70385-0](#)

**TRIBUTE (65279;Herbst), :**

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2005;23:5892-9 [[16043829](#)] [10.1200/JCO.2005.02.840](#)

**Gatzemeier , :**

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. *J Clin Oncol* 2007;25:1545-52 [[17442998](#)] [10.1200/JCO.2005.05.1474](#)

**Mok , :**

Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. *J Clin Oncol* 2009;27:5080-7 [[19738125](#)] [10.1200/JCO.2008.21.5541](#)

**SATURN (Cappuzzo), :**

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenias S, Szczsna A, Juhsz E, Esteban E, Molinier O, Brugger W, Meleznek I, Klingelschmitt G, Klughammer B, Giaccone G Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2010;11:521-9 [[20493771](#)] [10.1016/S1470-2045\(10\)70112-1](#)

**Boutsikou, :**





Tartrate, Seloken, Betaloc, Betaloc-Astra, Betaloc Astra, BetalocAstra, CGP-2175, CGP 2175, CGP2175, , nebivolol, nebivolol hydrochloride, Silostar, Uriach brand of nebivolol hydrochloride, Nebilet, Lobivon, Menarini brand of nebivolol hydrochloride, Berlin-Chemie brand of nebivolol hydrochloride, R 67555, R-67555, , Niacin, Nicotinic Acid, 3-Pyridinecarboxylic Acid, 3 Pyridinecarboxylic Acid, Induracin, Niacin Ammonium Salt, Niacin Calcium Salt, Niacin Cobalt (2+) Salt, Niacin Lithium Salt, Niacin Magnesium Salt, Niacin Manganese (2+) Salt, Niacin Potassium Salt, Niacin Sodium Salt, Niacin Tartrate, Niacin Copper (2+) Salt, Niacin Hydrochloride, Niacin Iron (2+) Salt, Niacin Tosylate, Niacin Zinc Salt, Nicamin, Nico-400, Nico 400, Nico400, Nicobid, Nicocap, Nicolar, Nicotinate, Wampocap, Enduracin, Lithium Nicotinate, Niacin Aluminum Salt, , (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline, SQ-14534, SQ 14534, SQ14534, SQ-14225, SQ 14225, SQ14225, Capoten, Lopirin, , dipyridamole monoacetate, dipyridamol monoacetate, , Digoxin, Digacin, Digitek, Digoregen, Lanoxin, Lanoxin-PG, Lanoxin PG, Lenoxin, Digoxine Nativelle, Hemigoxine Nativelle, Dilanacin, Lanacordin, Lanicor, Lanoxicaps, Mapluxin, Digoxina Boehringer, , Dicumarol, Dicoumarol, Bishydroxycoumarin, Dicoumarin, , CYPHER TAXUS Promus Xience Biomatrix Nobori Endeavor, Drug-Eluting Stents, Drug Eluting Stents, Drug-Eluting Stent, Drug-Coated Stents, Drug Coated Stents, Drug-Coated Stent, , Multaq, Zetia, Ezetrol, Felodipine, Felo Biochemie, Felo-Puren, Felo Puren, Felobeta, Felocor, Felodipin 1A Pharma, Felodipin AbZ, Felodipin AL, Felodipin AZU, Felodipin dura, Felodur, Felogamma, Fensel, H 154-82, H 154 82, H 15482, Plendil, Flodil, Modip, Renedil, Munobal, Felodipin Heumann, Felodipin Stada, felodipin von ct, Felodipin-ratiopharm, Felodipin ratiopharm, Perfudal, Agon, , Procetofen, Flecainide, Flecatab, Flecainide Acetate, Flecainide Monoacetate, R818, Tambocor, Apocard, Flcane, Flecadura, Flecainid-Isis, Flecainid Isis, , Fish Oils, Fish Liver Oils, , fluvastatin, fluindostatin, Lescol, XU 62-320, XU-62320, XU 62320, fluvastatin sodium, fluvastatin sodium salt, , Quixidar, Arixtra, Fosinopril, Fosenopril, Monopril, Staril, Fosinorm, Newace, Hiperlex, Fozitec, Fosinil, Fositens, Dynacil, Tenso Stop, Tensocardil, Fosinopril Sodium, SQ-28555, SQ 28555, SQ28555, , Nadroparin, Nadroparine, Nadroparin Calcium, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , Furosemide, Frusemide, Fursemide, Frusemid, Furanthril, Furantral, Salix (brand of furosemide), Furosemide Monosodium Salt, Fusid, Lasix, Errolon, Furosemide Monohydrochloride, , Gemfibrozil, Gemfibrosil, Terry White Chemists Gemfibrozil, Bolutol, Chem mart Gemfibrozil, CI-719, CI 719, CI719, DBL Gemfibrozil, Trialmin, Decrelip, Gemfi 1A Pharma, Gemfibrozilo Bayvit, Gemfibrozilo Bexal, Gemfibrozilo Ur, Gemhexal, Gen-Gemfibrozil, Gen Gemfibrozil, GenGemfibrozil, GenRX Gemfibrozil, Healthsense Gemfibrozil, Jezil, Lipazil, Lipox Gemfi, Litarek, Lopid, Lopid R, Lipur, Novo-Gemfibrozil, Novo Gemfibrozil, Nu-Gemfibrozil, Nu Gemfibrozil, NuGemfibrozil, Pilder, PMS-Gemfibrozil, PMS Gemfibrozil, SBPA Gemfibrozil, Apo-Gemfibrozil, Apo Gemfibrozil, ApoGemfibrozil, Ausgem, , gemfibrozil 1-O-acylglucuronide, 1-O-gemfibrozil-beta-D-glucuronide, , Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , Labetalol, Labetolol, Albetol, Apo-Labetalol, Apo Labetalol, ApoLabetalol, Dilevalol, Normodyne, Presolol, SCH-19927, SCH 19927, SCH19927, Trandate, AH-5158, AH 5158, AH5158, Labetalol Hydrochloride, , Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , Nicardipine, Cardene SR, Dagan, Flusemide, Lecibral, Lincil, Loxen, Lucefal, Nicardipine Hydrochloride, Nicardipine LA, Nicardipino Ratiopharm, Nicardipino Seid, Perdipine, Ridene, Y-93, Y 93, Y93, Cardene I.V., Cardene, Vasonase, Antagonil, , Nicorandil, 2-Nicotinamidoethyl Nitrate, 2 Nicotinamidoethyl Nitrate, 2-Nicotinamidethyl Nitrate, 2 Nicotinamidethyl Nitrate, SG-75, SG 75, SG75, Ikorel, Adancor, Dancor, , Nifedipine, Adalat, Bay-1040, Bay 1040, Bay1040, BAY-a-1040, BAY a 1040, BAYa1040, Procardia XL, Nifedipine-GTIS, Nifedipine GTIS, Corinfar, Korinfar, Fenigidin, Nifangin, Nifedipine Monohydrochloride, Procardia, Vascard, Cordipin, Cordipine, , Nitroglycerin, Glyceryl Trinitrate, Nitrolan, Nitrostat, Perlinganit, Susadrin, Sustac, Sustak, Sustonit, Transderm Nitro, Tridil, Trinitrin, Trinitrolong, Anginine, Dynamite, Gilustenon, Nitrangin, Nitro-Bid, Nitro Bid, NitroBid, Nitro-Dur, Nitro Dur, NitroDur, Nitrocard, Nitroderm, Nitroderm TTS, Nitroglyn, Nitrol, Nitrong, Nitrospan, , omapatrilat, Vanlev, BMS 186716, BMS-186716, , Omacor, Lovaza, omega-3 ethyl ester 90, P-OM3 adjunct, , Logiparin, LHN-1, , orlistat, tetrahydrolipstatin, THLP, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate, Alli, GlaxoSmithKline brand of orlistat, Xenical, Roche brand of orlistat, Hoffmann-La Roche brand of orlistat, , Pentoxifylline, Oxpentifylline, BL-191, BL 191, BL191, Trental, Torental, Agapurin, Pentoxil, , Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine, , Actos, Practolol, ICI-50172, ICI 50172, ICI50172, Dalzic, Eralzdin Practolol, , Pravastatin, Eptastatin, Liplat, RMS-431, RMS 431, RMS431, SQ-31000, SQ 31000, SQ31000, Vasten, Bristacol, CS-514, CS 514, CS514, Lipemol, Prareduct, Mevalotin, Pravachol, Elisor, Selektine, Pravacol, Pravasin, Lipostat, , prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient, Probuco, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir, , Propranolol, Propanolol, Avlocardyl, AY-20694, AY 20694, AY20694, Betadren, Dexpropranolol, Inderal, Obsidan, Obzidan, Propranolol Hydrochloride, Rexigen, Anaprilin, Anapriline, Dociton, , Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285, , rimonabant, SR141716,

SR 141716, Acompla, Zimulti, Sanofi-Synthelabo brand of rimonabant, SR 141716A, SR141716A, SR-141716A, , Xarelto, BAY 59-7939, , Avandia, Crestor, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187, , Zocor, Darob, MJ-1999, MJ 1999, MJ1999, , telmisartan, Micardis, Boehringer Ingelheim brand of telmisartan, Abbott brand of telmisartan, BIBR 277, BIBR-277, Pritor, GlaxoSmithKline brand of telmisartan, Glaxo Wellcome brand of telmisartan, , tenecteplase, Metalyse, Boehringer Ingelheim brand of tenecteplase, TNKase, Hoffmann-La Roche brand of tenecteplase, Genentech brand of tenecteplase, , Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid, , Timolol, Timoptic, Timoptol, Timolol Hemihydrate, Timacar, Timolol Maleate, MK-950, MK 950, MK950, Optimol, Blocadren, , tinzaparin, tinzaparin sodium, Innohep, Leo brand of tinzaparin sodium, Bristol-Myers Squibb brand of tinzaparin sodium, , tirofiban, N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Agrastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462, , tolvaptan, OPC 41061, OPC-41061, Samsca, , topiramate, Topamax, , , Epitamax, McN 4853, McN-4853, , trandolapril, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid, Odrik, Hoechst brand of trandolapril, Aventis brand of trandolapril, Aventis Pharma brand of trandolapril, Udrik, Alter brand of trandolapril, RU 44570, RU44570, RU-44570, Mavik, Gopten, Abbott brand of trandolapril, Knoll brand of trandolapril, , triflusal, 2-acetoxy-4-trifluoromethylbenzoic acid, Disgren, Centrophne, Vastarel, Idaptan, Trimezidine Irex, Vasartel, Trimetazidine Dihydrochloride, , Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, , valsartan, N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine, Diovan, Tareg, Novartis brand of valsartan, Kalpress, Lacer brand of valsartan, Miten, CEPA brand of valsartan, Provas, Schwarz brand of valsartan, Sanol brand of valsartan, Vals, Esteve brand of valsartan, walsartan, CGP 48933, Nisis, Aventis brand of valsartan, , Verapamil, Iproveratril, Cordilox, Dexverapamil, Falicard, Izoptin, Isoptine, Isoptin, Lekoptin, Verapamil Hydrochloride, Calan, Finoptin, , vesnarinone, OPC 8212, OPC-8212, , Xamoterol, Corwin, ICI-118587, ICI 118587, ICI118587, Xamoterol Fumarate, Xamoterol Hemifumarate, Xamoterol Monohydrobromide, Xamoterol Monohydrochloride, Xamtol, Carwin, Xamoterol Maleate (2:1), , ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95, , Glucotrol, reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium, , Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Rytmogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecofen, , , nateglinide, nate-glinide, senaglinide, IPCCPA, N-((4-isopropylcyclohexyl)carbonyl)phenylalanine, AY 4166, AY-4166, DJN 608, Starsis, Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , Bay K 5552, , Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin, , Integrilin, Integrelin, reteplase, Retavase, Centocor brand of reteplase, Biovail brand of reteplase, Rapilysin, Roche brand of reteplase, , BetaxololSL-75212SL 75212SL75212BetopticBetoptimaBetaxolol AlconAlcon, BetaxololAlcon Brand of Betaxolol HydrochlorideAllphar Brand of Betaxolol HydrochlorideKerloneOxodalLorex Brand of Betaxolol HydrochlorideSynthelabo Brand of Betaxolol HydrochlorideBoots Brand of Betaxolol HydrochlorideSchwarz Brand of Betaxolol HydrochlorideSynthelabo Brand of Betaxolol HydrochlorideKerlonSearle Brand of Betaxolol HydrochlorideALO-1401-02ALO 1401 02ALO140102Betaxolol HydrochlorideHydrochloride, Betaxolol, Lipitor, torcetrapib, CP 529414, CP529414, CP-529414, , CYPHER, Cordis CYPHER, XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, Endeavour, Medtronic Endeavour, albiglutide, , liraglutide, victoza, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR, , sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431, , Acenocoumarol, Nicoumalone, Acenocoumarin, Synthrome, Synthrom, Syncoumar, Syncumar, Sinkumar, Sintrom, Mini-Sintrom, Mini Sintrom, MiniSintrom, , Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , Bepridil Monohydrochloride, Vascor, Bedapin, CERM-1978, CERM 1978, CERM1978, 1978-CERM, 1978 CERM, 1978CERM, Cordium, Unicordium, Bepadin, , Ethyl Chlorophenoxyisobutyrate, Atromid, Atromid S, Miscleron, Miskleron, Athromidin, , elinogrel, PRT



060128, PRT060128, PRT-060128, , Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natrecor, , Phenindione, Phenylindanedione, Phenylene, Pindione, Fenilin, Dindevan, , repaglinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW, , Brilique, Brilinta, AZD 6140, AZD6140, AZD-6140, zofenopril, Zofenil, Menarini brand of zofenopril, Zofil, SQ 26900, SQ-26900, SQ 26991, SQ-26991, , SQ 26703, zofenopril-SH, zofenopril-SH cpd with arginine, , MK 0859, MK0859, MK-0859, , PRT054021, , blufomedil, bufomedil, Buflor AbZ, AbZ brand of buflofomedil hydrochloride, Buflor-POS, Ursapharm brand of buflofomedil hydrochloride, Buflor-Puren, Alpharma brand of buflofomedil hydrochloride, Buflorhexal, Hexal brand of buflofomedil hydrochloride, Buflorimedil Heumann, Heumann brand of buflofomedil hydrochloride, buflofomedil hydrochloride, Buflorimedil Lindo, Lindopharm brand of buflofomedil hydrochloride, buflofomedil pyridoxal phosphate, Buflorimedil Stada, Stadapharm brand of buflofomedil hydrochloride, buflofomedil von ct, ct-Arzneimittel brand of buflofomedil hydrochloride, Buflorimedil-ratiopharm, ratiopharm brand of buflofomedil hydrochloride, Fonzylane, Lafon brand of buflofomedil hydrochloride, LL 1656, Loftyl, Bufedil, Lofton, Abbott brand of buflofomedil hydrochloride, Sinoxis, Hosbon brand of buflofomedil hydrochloride, Buflor 1A Pharma, 1A brand of buflofomedil hydrochloride, , Folic Acid, Vitamin M, Pteroylglutamic Acid, Folate, Folvite, Folacin, , Hydrochlorothiazide, HCTZ, Dichlothiazide, Dihydrochlorothiazide, HydroDIURIL, Oretic, Sectrazide, Esidrix, Esidrex, Hypothiazide, , inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27, , voglibose, Basen, , Trepidil, Trapymine, Rocornal, , desdiethyltrapidil, N-dediethyltrapidil, desdiethyl-trapidil, , certoparin, certoparin sodium, Mono-Embolex, Novartis brand of certoparin sodium, Alphaparin, Grifols brand of certoparin sodium, , glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxyglimepiride, hydroxy-glimepiride, , Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356, , taspoglutide, , miti-glinide, KAD 1229, KAD-1229, , transcatheter aortic valve implantation, , sibutramine, Meridia, mono-desmethylsibutramine, BTS 54 524, BTS-54524, BTS 54524, Reductil, di-desmethylsibutramine, didesmethylsibutramine, (R)-DDMS, sibutramine hydrochloride, , saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , eplerenon, Inspra, CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100, , SYR 322, SYR322, SYR-322, , benfluramate, benfluorex maleate, SE 780, 780 SE, JP 992, Mediator trade name of benfluorex hydrochloride, Biopharma brand of benfluorex hydrochloride, Modulator trade name of benfluorex hydrochloride, Servier brand of benfluorex hydrochloride, S 780, benfluorex hydrochloride, 1-(2-trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl, , Coronary Artery Bypass, Coronary Artery Bypasses, Coronary Artery Bypass Surgery, Aortocoronary Bypass, Aortocoronary Bypasses, Coronary Artery Bypass Grafting, CABG, AR C69931MX, AR-C69931MX, , Carotid Endarterectomy, Carotid Endarterectomies, , Chlortalidone, Phthalamudine, Chlorphthalidolone, Oxodoline, Thalitone, Hygroton, , dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798, , docetaxol, Taxolteretro, Taxotere, NSC 628503, RP 56976, RP-56976, ebselen, PZ 51, PZ-51, RP 60931, DR 3305, DR-3305, , Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide, , Exercise Therapy, Exercise Therapies, , Gene Therapy, DNA Therapy, Somatic Gene Therapy, , Ginkgo biloba, Ginkgo bilobas, Ginko, Ginkos, Ginkgo, Ginkgos, Gingko, Gingkos, Maidenhair Tree, Maidenhair Trees, Ginkgo biloba, Ginkgo bilobas, Ginkgophyta, Ginkgophytas, , Lacipil, Lacimen, Caldine, Motens, GR 43659X, GR-43659X, , olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec, , h5G1.1-scFv, pexelizumab, , Dalteparin, Tedelparin, Kabi-2165, Kabi 2165, Kabi2165, Fragmin, Fragmine, Dalteparin Sodium, FR-860, FR 860, FR860, , efegatran, Me-Phe-Pro-Arg-H, D-methyl-phenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efegatran sulfate, , etofibrate, Lipo-Merz, Merz brand of etofibrate, Tricerol, Armstrong brand of etofibrate, etofibrate hydrochloride, , simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259, , ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, , primary balloon angioplasty, primary PTCA, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus, , Gliclazide, Glyclazide, Gliklazid, Diamicon, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide, , Qnexa, Zontivity, SCH 530348, SCH530348, SCH-530348, , MDX-1106, ONO-4538, BMS-936558, Opdivo, lambrolizumab, Keytruda, MK-3475, , MDX-CTLA-4, Yervoy, DX 010, MDX010, MDX-010, , Iressa, ZD1839, ZD 1839, , Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican, , pertuzumab, Perjeta, Omnitarg, ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-DM1 conjugate, T-DM1 cpd, trastuzumab emtansine, huN901-DM1, Kadcyca, Avastin, , gemcitabine, dFdCyd, 2'-deoxy-2'-difluorocytidine, gemcitabine hydrochloride, LY 188011, LY-188011, Gemzar, , Toremifene, Toremifene Citrate, Toremifene Citrate (1:1), Fareston, FC-1157a, FC 1157a, FC1157a, , Xeloda, , Cisplatin, cis-Diamminedichloroplatinum(II),

Platinum Diamminodichloride, cis-Platinum, cis Platinum, Dichlorodiammineplatinum, cis-Diamminedichloroplatinum, cis Diamminedichloroplatinum, cis-Dichlorodiammineplatinum(II), NSC-119875, Platino, Platinol, Biocisplatinum, Platidiam, , ICI 182780, ICI-182780, ZM 182780, ZM-182780, Faslodex, , palbociclib, Ibrance, PD 0332991, PD0332991, PD-0332991, anastrozole, anastrazole, ICI D1033, ZD-1033, Zeneca ZD 1033, ZD1033, Arimidex, letrozole, Femara, Fmara, CGS 20267, CGS-20267, Aminoglutethimide, Cytadren, Orimeten, formestane, 4-hydroxyandrostenedione, 4-OHA, Lentaron, CGP-32349, CGP 32 349, CGP 32349, , exemestane, FCE 24304, FCE-24304, Aromasil, Aromasin, Aromasine, , Fadrozole, CGS-16949A, CGS 16949A, CGS16949A, Fadrozole Hydrochloride, Fadrozole Monohydrochloride, CGS 020286A, CGS020286A, CGS-020286A, FAD 286, FAD286, FAD-286, , Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox, ixabepilone, BMS247550, BMS-247550, BMS 247550, Herceptin, Torisel, CCI 779, CCI-779, , alirocumab, REGN727 monoclonal antibody, monoclonal antibody REGN727, SAR236553, Praluent, , AMG 145, evolocumab, AMG-145, Repatha, Medroxyprogesterone Acetate, Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17 Acetate, Depo-Medroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, Curretab, Cycrin, Depo-Provera, Depo Provera, DepoProvera, Farlutal, Perlutex, Provera, Veramix, Clinovir, Gestapuran, sorafenib, sorafenib N-oxide, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate, BAY 545-9085, BAY-545-9085, sorafenib tosylate, BAY 43-9006, Nexavar, , entinostat, SNDX-275, MS 27-275, MS-275, MS 275, MS-27-275, B 1939, B-1939, E 7389, E-7389, Halaven, NSC 707389, NSC707389, NSC-707389, B 1793, B-1793, ER-086526, ER086526, ER 086526, ER-86526, , Abraxane, vinorelbine, 5'-nor-anhydrovinblastine, Navelbine, vinorelbine tartrate, KW 2307, KW-2307, , intensive treatment, tighter control of blood pressure, low target blood pressure, strict blood pressure control, intensified blood-pressure control, IMC C225, IMC-C225, MAb C225, C225, Erbitux, , Tarceva, CP 358774, CP-358774, OSI-774, Inlyta, AG 013736, AG013736, AG-013736, , TKI 258, TKI258, TKI-258, dovitinib, CHIR 258, CHIR258, CHIR-258, , GW 786034B, GW786034B, GW-786034B, GW 780604, GW780604, GW-780604, Votrient, , Sutent, SU 11248, SU11248, SU-11248, SU011248, SU 011248, SU-011248, , D2E7 Antibody, Humira, Cimzia, Cimzias, CDP870, CDP870s, CDP 870, CDP 870s, , TNF Receptor Type II-IgG Fusion Protein, TNF Receptor Type II IgG Fusion Protein, Enbrel, Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein, Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein, TNFR-Fc Fusion Protein, TNFR Fc Fusion Protein, TNR-001, TNR001, TNR 001, TNT Receptor Fusion Protein, TNTR-Fc, , Simponi, , MAb cA2, Monoclonal Antibody cA2, Remicade, , Interleukin 1 Receptor Antagonist Protein, Urine-Derived IL1 Inhibitor, Urine Derived IL1 Inhibitor, IL1 Febrile Inhibitor, Urine IL-1 Inhibitor, IL-1Ra, Antril, Kineret, Anakinra, , tocilizumab, atlizumab, Actemra, , Rituxan, MabThera, Zytux, Rituximab, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, IDEC C2B8 Antibody, IDECC2B8 Antibody, IDEC-C2B8, IDEC C2B8, IDECC2B8, GP2013, Rituxan, , tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550, , durvalumab, Imfinzi, MPDL3280A, Tecentriq, RG7446, RG-7446, , MTA, Pemetrexed Disodium, LY 231514, LY231514, LY-231514, Alimta, , rolofylline, KW 3902, KW-3902, MK 7418, MK7418, MK-7418, , BG 9928, BG-9928, BG9928, BIO 4683, BIO4683, BIO-4683, BIO 5770, BIO5770, BIO-5770, BIO 8170, BIO8170, BIO-8170, BIO 9002, BIO9002, BIO-9002, tonapofylline, BIO 7505, BIO7505, BIO-7505, , Invokana, , BI 10773, BI10773, BI-10773, Jardiance, , dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148, , avelumab, MSB0010718C, , Xalkori, PF-02341066, PF02341066, PF 02341066, , BAY 94-8862, finerenone, , AZD 2281, AZD2281, AZD-2281, AZD221, Lynparza, , 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, niraparib hydrochloride, MK 4827, MK4827, MK-4827, , BMN 673, , 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, ABT 888, ABT888, ABT-888, , bococizumab, , CH5424802, alectinib, RO5424802, , ceritinib, Zykadia, LDK378, , AP26113, brigatinib, , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima, , imetelstat, motesanib, motesanib diphosphate, AMG 706, AMG706, AMG-706, , aflibercept, VEGF Trap-Eye, VEGF Trap - regeneron, VEGF-Trap, AVE 005, AVE005, AVE-005, Zaltrap, ZIV-aflibercept, AVE 0005, AVE0005, AVE-0005, eylea, , osimertinib, Tagrisso,

## 4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent

therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.